Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics

Immune checkpoint inhibitors (ICIs) are considered a new standard-of-care across many cancer indications. This review provides an update on ICIs approved by the Food and Drug Administration (FDA), with focus on monoclonal antibodies that target the programmed cell death 1 (PD-1) or its ligand, PD-1...

Full description

Saved in:
Bibliographic Details
Published inThe AAPS journal Vol. 23; no. 2; p. 39
Main Authors Twomey, Julianne D., Zhang, Baolin
Format Journal Article
LanguageEnglish
Published Cham Springer International Publishing 07.03.2021
Subjects
Biochemistry
Biomedical and Life Sciences
Biomedicine
Biotechnology
Pharmacology/Toxicology
Pharmacy
Review
Review Article
Theme: Identification and Implementation of Predictive Biomarkers for Checkpoint Targeted Immunotherapy
immune checkpoint inhibitor
companion diagnostic
biomarker
cancer immunotherapy
Online AccessGet full text

Cover

More Information
Summary:Immune checkpoint inhibitors (ICIs) are considered a new standard-of-care across many cancer indications. This review provides an update on ICIs approved by the Food and Drug Administration (FDA), with focus on monoclonal antibodies that target the programmed cell death 1 (PD-1) or its ligand, PD-1 ligand 1 (PD-L1), including information on their clinical indications and associated companion diagnostics. The information is further discussed with strategies for identifying predictive biomarkers to guide the clinical use of PD-1/PD-L1-targeted therapies.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Guest Editors: Baolin Zhang and Mario L. Rocci Jr.
ISSN:1550-7416
1550-7416
DOI:10.1208/s12248-021-00574-0